CytomX Therapeutics EBITDA 2014-2022 | CTMX
CytomX Therapeutics ebitda from 2014 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
CytomX Therapeutics Annual EBITDA
(Millions of US $) |
| 2021 |
$-81 |
| 2020 |
$-46 |
| 2019 |
$-111 |
| 2018 |
$-78 |
| 2017 |
$-44 |
| 2016 |
$-56 |
| 2015 |
$-31 |
| 2014 |
$-29 |
| 2013 |
$-14 |
CytomX Therapeutics Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-23 |
| 2021-12-31 |
$-26 |
| 2021-09-30 |
$-22 |
| 2021-06-30 |
$-18 |
| 2021-03-31 |
$-15 |
| 2020-12-31 |
$-14 |
| 2020-09-30 |
$-14 |
| 2020-06-30 |
$-16 |
| 2020-03-31 |
$-2 |
| 2019-12-31 |
$-37 |
| 2019-09-30 |
$-26 |
| 2019-06-30 |
$-31 |
| 2019-03-31 |
$-17 |
| 2018-12-31 |
$-26 |
| 2018-09-30 |
$-23 |
| 2018-06-30 |
$-13 |
| 2018-03-31 |
$-15 |
| 2017-12-31 |
$-1 |
| 2017-09-30 |
$-10 |
| 2017-06-30 |
$-25 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-13 |
| 2016-09-30 |
$-14 |
| 2016-06-30 |
$-13 |
| 2016-03-31 |
$-15 |
| 2015-12-31 |
$-11 |
| 2015-09-30 |
$-11 |
| 2015-06-30 |
$-5 |
| 2015-03-31 |
$-4 |
| 2014-12-31 |
|
| 2014-09-30 |
$-3 |
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
